SCHEMBL3243876

SCHEMBL3243876

C=Cc1c(Cl)cnc2ccc(OC)cc12

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SRC P12931 1/20 0.43
KDM4E B2RXH2 2/20 0.42
MAPK1 P28482 1/20 0.42
NPSR1 Q6W5P4 1/20 0.42
SMN1; SMN2 Q16637 2/20 0.41
LMNA P02545 1/20 0.40
GABRA1 P14867 2/20 0.40
GABRG2 P18507 2/20 0.40
GABRB3 P28472 2/20 0.40
GABRA5 P31644 2/20 0.40
GABRA3 P34903 2/20 0.40
MAPT P10636 2/20 0.40
GABRA2 P47869 1/20 0.40
GRM1 Q13255 1/20 0.40
HTR1A P08908 1/20 0.39
ADRA1D P25100 1/20 0.39
ADRA1A P35348 1/20 0.39
ADRA1B P35368 1/20 0.39
EGFR P00533 2/20 0.39
ROCK2 O75116 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27632917 0.87 SMN1; SMN2 (0.43) SRCKDM4EMAPK1NPSR1SMN1; SMN2
SCHEMBL2942171 0.85 ALDH1A1 (0.45) SRCKDM4EMAPK1NPSR1SMN1; SMN2
SCHEMBL2954867 0.82 KDM4E (0.42) KDM4EMAPK1NPSR1LMNAGABRA1
SCHEMBL5749051 0.82 KDM4E (0.42) KDM4EMAPK1NPSR1SMN1; SMN2LMNA
SCHEMBL5747879 0.80 NR4A2 (0.42) LMNAGABRA1GABRG2GABRB3GABRA5
SCHEMBL4854654 0.79 SRC (0.41) SRCKDM4EMAPK1NPSR1SMN1; SMN2
SCHEMBL3273397 0.79 MAP2K1 (0.52) SRCKDM4ENPSR1MAPTEGFR
SCHEMBL14400286 0.78 KDM4E (0.48) SRCKDM4ESMN1; SMN2LMNAGABRA1
SCHEMBL5747612 0.77 LMNA (0.39) LMNAHTR1AALDH1A1
SCHEMBL440060 0.77 BCHE (0.50) SRCKDM4ENPSR1LMNAMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2181996-A1 Aminopiperidine derivatives GLAXO GROUP LIMITED (GB) 2010-05-05 EP disclosed
US-7312212-B2 Aminopiperidine derivatives GLAXO GROUP LIMITED (GB) 2007-12-25 US disclosed
US-20070244103-A1 Novel Compounds Having an Anti-Bacterial Activity MORPHOCHEM AKTIENGESELLSCHAFT FUR KOMBINATORISCHE CHEMIE (DE) 2007-10-18 US disclosed
EP-1578743-A4 ANTIBACTERIAL AGENTS GLAXO GROUP LTD (GB) 2006-11-29 EP disclosed
US-20060041123-A1 Antibacterial agents GLAXO GROUP LIMITED (GB) 2006-02-23 US disclosed
EP-1578743-A2 ANTIBACTERIAL AGENTS GLAXO GROUP LIMITED (GB) 2005-09-28 EP disclosed
US-20050159411-A1 Aminopiperidine derivatives GLAXO GROUP LIMITED (GB) 2005-07-21 US disclosed
EP-1470125-A1 AMINOPIPERIDINE DERIVATIVES GLAXO GROUP LIMITED (GB) 2004-10-27 EP disclosed
WO-2004058144-A2 ANTIBACTERIAL AGENTS GLAXO GROUP LIMITED (GB) 2004-07-15 WO disclosed
WO-2003064421-A1 AMINOPIPERIDINE DERIVATIVES GLAXO GROUP LIMITED (GB) 2003-08-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070244103-A1 Novel Compounds Having an Anti-Bacterial Activity TOP1, TOP2A, TOP2B SRC 4853/4885KDM4E 2755/4885MAPK1 2275/4885
US-20060041123-A1 Antibacterial agents NQO2, NRDC, IFNG SRC 4760/4885KDM4E 4544/4885MAPK1 2560/4885
US-20050159411-A1 Aminopiperidine derivatives AMPD2, AMPD3, NPEPPS SRC 4413/4885KDM4E 2819/4885MAPK1 4202/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.